On April 7, two federal courts issued conflicting rulings concerning FDA approval of mifepristone. The holding in Alliance for Hippocratic Medicine v. FDA resulted in a preliminary injunction that imposes a nationwide “stay” of FDA’s approval of this drug. Washington v. FDA, however, resulted in a preliminary injunction enjoining FDA from suspending access to the drug in 17 states and the District of Columbia. DOJ has appealed to the Supreme Court to restore full access to this drug and the SCOTUS decision is imminent. How will these judicial decisions affect the medical community and patients? What are FDA’s options in responding to these two conflicting cases? What are the broader implications for FDA and drug manufacturers around product approvals?

Get Access

  • +$100 for nonmembers


Kelly F. Goldberg, Vice President, Law/ Senior Counsel for Biopharmaceutical Regulation, PhRMA
Lewis A. Grossman, Professor of Law, American University
Jordan K. Paradise, Georgia Reithal Professor of Law, Loyola University – Chicago
Eva Temkin, Partner, King & Spalding LLP
Moderated by Vanessa K. Burrows, Counsel, Simpson Thacher & Bartlett

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content